FDMT FY 2020 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+94.8% YoY

Gross Profit

-$39M-289.6% margin

Operating Income

-$57M-416.3% margin

Net Income

-$57M-416.5% margin

EPS (Diluted)

$-2.12

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$52M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$288M

Total Liabilities

$32M

Stockholders' Equity

$256M

Cash & Equivalents

$277M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$7M	+94.8%
Gross Profit	-$39M	-$32M	-24.2%
Operating Income	-$57M	-$51M	-11.6%
Net Income	-$57M	-$49M	-15.0%